HK1030625A1 - Methods and compositions for immunomodulation - Google Patents
Methods and compositions for immunomodulationInfo
- Publication number
- HK1030625A1 HK1030625A1 HK01101094A HK01101094A HK1030625A1 HK 1030625 A1 HK1030625 A1 HK 1030625A1 HK 01101094 A HK01101094 A HK 01101094A HK 01101094 A HK01101094 A HK 01101094A HK 1030625 A1 HK1030625 A1 HK 1030625A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methods
- compositions
- protein
- useful
- disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6476497P | 1997-11-07 | 1997-11-07 | |
PCT/CA1998/001038 WO1999024565A1 (en) | 1997-11-07 | 1998-11-06 | Methods and compositions for immunomodulation |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1030625A1 true HK1030625A1 (en) | 2001-05-11 |
Family
ID=22058127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK01101094A HK1030625A1 (en) | 1997-11-07 | 2001-02-15 | Methods and compositions for immunomodulation |
Country Status (13)
Country | Link |
---|---|
US (6) | US6338851B1 (xx) |
EP (1) | EP1032662B1 (xx) |
JP (2) | JP4584447B2 (xx) |
AT (1) | ATE319825T1 (xx) |
AU (1) | AU748587B2 (xx) |
CA (1) | CA2308765C (xx) |
CY (1) | CY1105364T1 (xx) |
DE (1) | DE69833779T2 (xx) |
DK (1) | DK1032662T3 (xx) |
ES (1) | ES2260852T3 (xx) |
HK (1) | HK1030625A1 (xx) |
PT (1) | PT1032662E (xx) |
WO (1) | WO1999024565A1 (xx) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1032662B1 (en) | 1997-11-07 | 2006-03-08 | Trillium Therapeutics Inc. | Methods and compositions for immunomodulation |
US7223729B2 (en) | 1997-11-07 | 2007-05-29 | Trillium Therapeutics Inc. | Methods of treating allergy by administering a CD200 protein |
US6955811B2 (en) | 1997-11-07 | 2005-10-18 | Trillium Therapeutics Inc. | Methods of inhibiting immune response suppression by administering antibodies to OX-2 |
MXPA01010480A (es) * | 1999-04-13 | 2002-03-27 | Schering Corp | Usos novedosos de la proteina 0x2 de mamifero y reactivos relacionados. |
US20020192215A1 (en) * | 1999-04-13 | 2002-12-19 | Schering Corporation, A New Jersey Corporation | Novel uses of mammalian OX2 protein and related reagents |
AU6615500A (en) * | 1999-07-28 | 2001-02-19 | Genetics Institute Inc. | Preventing immune-mediated abortion by inhibiting costimulation |
AU4215901A (en) | 2000-03-17 | 2001-09-24 | Reginald M Gorczynski | Methods and compositions for immunoregulation |
ES2292587T3 (es) * | 2000-04-22 | 2008-03-16 | Pharmedartis Gmbh | Agentes apoptoticos. |
WO2002011762A2 (en) * | 2000-08-03 | 2002-02-14 | Gorczynski Reginald M | Methods and compositions for modulating tumor growth |
AUPR069500A0 (en) * | 2000-10-11 | 2000-11-09 | Coster, Douglas John | Tissue modification |
JP2004513660A (ja) * | 2000-11-22 | 2004-05-13 | トリリウム セラピューティクス インコーポレーティッド | 切断型cd200 |
US20040198661A1 (en) * | 2000-12-08 | 2004-10-07 | Bowdish Katherine S. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
AU2002246632B2 (en) | 2000-12-08 | 2007-04-05 | Alexion Pharmaceuticals, Inc. | Chronic lymphocytic leukemia cell line and its use for producing an antibody |
US20060057651A1 (en) * | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US7408041B2 (en) | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US9249229B2 (en) | 2000-12-08 | 2016-02-02 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US6906237B2 (en) * | 2001-02-27 | 2005-06-14 | G. Scott Herron | Vivo assay for anti angiogenic compounds |
US7285631B2 (en) | 2001-08-10 | 2007-10-23 | Serono Genetics Institute S.A. | Human cDNAs and proteins and uses thereof |
EP1439857B1 (en) * | 2001-10-12 | 2009-02-25 | Schering Corporation | USE OF BISPECIFIC ANTIBODIES BINDING TO THE ACTIVATING RECEPTOR FcEpsilonRI AND TO THE INHIBITING RECEPTOR OX2Ra (CD200Ra) TO REGULATE IMMUNE RESPONSES |
US7196243B2 (en) | 2002-04-03 | 2007-03-27 | Trillium Therapeutics Inc. | Transgenic animal containing CD200 and uses therefor |
WO2004060295A2 (en) * | 2002-12-27 | 2004-07-22 | Schering Corporation | Methods of inducing and maintaining immune tolerance |
US7741038B2 (en) | 2005-03-14 | 2010-06-22 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for evaluating graft survival in a solid organ transplant recipient |
USRE46843E1 (en) | 2005-03-14 | 2018-05-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for evaluating graft survival in a solid organ transplant recipient |
GB0506721D0 (en) * | 2005-04-01 | 2005-05-11 | Univ Glasgow | Soluble immunoregulatory factor |
NZ569903A (en) | 2006-01-12 | 2012-07-27 | Alexion Pharma Inc | Antibodies to OX-2/CD200 and uses thereof |
WO2008085963A1 (en) * | 2007-01-05 | 2008-07-17 | University Of Florida Research Foundation, Inc. | Materials and methods for the detection, prevention and treatment of autoimmune disease |
AU2008279618B2 (en) | 2007-07-25 | 2014-05-22 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating autoimmune disease |
JP2010534243A (ja) | 2007-07-25 | 2010-11-04 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | Cd200に対する抗体および免疫応答への使用 |
WO2010083121A1 (en) | 2009-01-15 | 2010-07-22 | The Board Of Trustees Of The Leland Stanford Junior University | Biomarker panel for diagnosis and prediction of graft rejection |
US9290813B2 (en) | 2009-12-02 | 2016-03-22 | The Board Of Trustees Of The Leland Stanford Junior University | Biomarkers for determining an allograft tolerant phenotype |
JP6012473B2 (ja) | 2010-01-11 | 2016-10-25 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 抗cd200抗体を用いたヒトの処置における免疫調節効果のバイオマーカー |
JP2013519682A (ja) | 2010-02-11 | 2013-05-30 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 抗cd200抗体を使用する治療方法 |
ES2628841T3 (es) | 2010-03-12 | 2017-08-04 | Alexion Pharmaceuticals, Inc. | Proteínas de fusión npp1 |
WO2012125182A1 (en) | 2011-03-11 | 2012-09-20 | Synageva Biopharma Corp | Npp1 fusion proteins |
EP2550371A4 (en) | 2010-03-25 | 2013-11-20 | Univ Leland Stanford Junior | PROTEIN AND GENE BIOMARKERS FOR EXTRACTING ORGAN TRANSPLANTS |
US11492383B2 (en) | 2011-06-24 | 2022-11-08 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
US9737598B2 (en) | 2014-06-30 | 2017-08-22 | Regents Of The University Of Minnesota | CD200 inhibitors and methods of use thereof |
EP3967755B1 (en) | 2014-12-19 | 2024-03-27 | Inozyme Pharma, Inc. | Soluble npp1 for use in a method for treating pseudoxanthoma elasticum |
US10888609B2 (en) | 2015-11-03 | 2021-01-12 | Regents Of The University Of Minnesota | CD200 inhibitors and methods of use thereof |
GB201608197D0 (en) * | 2016-05-10 | 2016-06-22 | Ducentis Biotherapeutics Ltd | Novel proteins |
WO2017218786A1 (en) | 2016-06-16 | 2017-12-21 | Alexion Pharmaceuticals, Inc. | Methods of treating myointimal proliferation |
TW201803905A (zh) | 2016-06-20 | 2018-02-01 | 克馬伯有限公司 | 用於免疫腫瘤學之多重專一性抗體 |
KR101968246B1 (ko) * | 2017-04-27 | 2019-04-11 | 서울대학교산학협력단 | 이종 각막 이식에서 항 cd20 단일클론항체 및 타클로리무스의 복합면역억제 방법 |
JP7511469B2 (ja) | 2017-09-27 | 2024-07-05 | イノザイム ファーマ, インコーポレイテッド | 組換えエクトヌクレオチドピロホスファターゼ/ホスホジエステラーゼ(npp1)を使用して心血管機能を改善し、心血管疾患を処置するための方法。 |
WO2019067499A1 (en) | 2017-09-27 | 2019-04-04 | Alexion Pharmaceuticals, Inc. | BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY |
WO2019084682A1 (en) | 2017-10-30 | 2019-05-09 | Mcmaster University | Methods for the diagnosis and treatment of endometriosis |
WO2019126536A1 (en) | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals Inc. | Humanized anti-cd200 antibodies and uses thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0606217B2 (en) * | 1991-06-27 | 2008-12-03 | Bristol-Myers Squibb Company | Ctl4a receptor, fusion proteins containing it and uses thereof |
GB9505653D0 (en) * | 1995-03-21 | 1995-05-10 | Shober Wharton | Method of pest control |
WO1997021450A1 (en) * | 1995-12-08 | 1997-06-19 | Brigham And Women's Hospital, Inc. | Ox-2 costimulatory molecule |
CA2246352C (en) * | 1996-03-20 | 2011-11-08 | Bristol-Myers Squibb Company | Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith |
EP1032662B1 (en) | 1997-11-07 | 2006-03-08 | Trillium Therapeutics Inc. | Methods and compositions for immunomodulation |
US7223729B2 (en) * | 1997-11-07 | 2007-05-29 | Trillium Therapeutics Inc. | Methods of treating allergy by administering a CD200 protein |
US20020192215A1 (en) * | 1999-04-13 | 2002-12-19 | Schering Corporation, A New Jersey Corporation | Novel uses of mammalian OX2 protein and related reagents |
AU4215901A (en) | 2000-03-17 | 2001-09-24 | Reginald M Gorczynski | Methods and compositions for immunoregulation |
JP2004513660A (ja) | 2000-11-22 | 2004-05-13 | トリリウム セラピューティクス インコーポレーティッド | 切断型cd200 |
CA2448668A1 (en) | 2001-05-24 | 2002-11-28 | Trillium Therapeutics Inc. | Modulation of cd200 receptors |
US7196243B2 (en) * | 2002-04-03 | 2007-03-27 | Trillium Therapeutics Inc. | Transgenic animal containing CD200 and uses therefor |
US7649023B2 (en) * | 2002-06-11 | 2010-01-19 | Novartis Ag | Biodegradable block copolymeric compositions for drug delivery |
-
1998
- 1998-11-06 EP EP98952476A patent/EP1032662B1/en not_active Revoked
- 1998-11-06 PT PT98952476T patent/PT1032662E/pt unknown
- 1998-11-06 WO PCT/CA1998/001038 patent/WO1999024565A1/en active IP Right Grant
- 1998-11-06 ES ES98952476T patent/ES2260852T3/es not_active Expired - Lifetime
- 1998-11-06 JP JP2000520560A patent/JP4584447B2/ja not_active Expired - Fee Related
- 1998-11-06 AU AU10173/99A patent/AU748587B2/en not_active Ceased
- 1998-11-06 AT AT98952476T patent/ATE319825T1/de active
- 1998-11-06 DK DK98952476T patent/DK1032662T3/da active
- 1998-11-06 CA CA2308765A patent/CA2308765C/en not_active Expired - Fee Related
- 1998-11-06 DE DE69833779T patent/DE69833779T2/de not_active Expired - Lifetime
-
2000
- 2000-05-05 US US09/570,367 patent/US6338851B1/en not_active Expired - Fee Related
-
2001
- 2001-02-15 HK HK01101094A patent/HK1030625A1/xx not_active IP Right Cessation
- 2001-07-27 US US09/915,524 patent/US6652858B2/en not_active Expired - Fee Related
- 2001-08-23 US US09/934,634 patent/US6749854B2/en not_active Expired - Fee Related
- 2001-09-10 US US09/948,725 patent/US6984625B2/en not_active Expired - Fee Related
-
2006
- 2006-06-05 CY CY20061100716T patent/CY1105364T1/el unknown
-
2009
- 2009-05-22 US US12/470,707 patent/US7902151B2/en not_active Expired - Fee Related
-
2010
- 2010-02-12 JP JP2010029085A patent/JP2010155846A/ja not_active Ceased
-
2011
- 2011-02-03 US US13/020,340 patent/US20110206668A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2308765C (en) | 2010-10-12 |
JP2010155846A (ja) | 2010-07-15 |
DE69833779T2 (de) | 2006-11-30 |
US20110206668A1 (en) | 2011-08-25 |
WO1999024565A1 (en) | 1999-05-20 |
JP2001522867A (ja) | 2001-11-20 |
EP1032662B1 (en) | 2006-03-08 |
PT1032662E (pt) | 2006-07-31 |
JP4584447B2 (ja) | 2010-11-24 |
ES2260852T3 (es) | 2006-11-01 |
US20090232825A1 (en) | 2009-09-17 |
US20020086011A1 (en) | 2002-07-04 |
CY1105364T1 (el) | 2010-03-03 |
US6984625B2 (en) | 2006-01-10 |
ATE319825T1 (de) | 2006-03-15 |
CA2308765A1 (en) | 1999-05-20 |
AU748587B2 (en) | 2002-06-06 |
EP1032662A1 (en) | 2000-09-06 |
US6749854B2 (en) | 2004-06-15 |
DE69833779D1 (de) | 2006-05-04 |
US20020151485A1 (en) | 2002-10-17 |
US6652858B2 (en) | 2003-11-25 |
US7902151B2 (en) | 2011-03-08 |
US6338851B1 (en) | 2002-01-15 |
AU1017399A (en) | 1999-05-31 |
US20020103151A1 (en) | 2002-08-01 |
DK1032662T3 (da) | 2006-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1030625A1 (en) | Methods and compositions for immunomodulation | |
PL328858A1 (en) | Immunogenous peptides | |
EP0687183A4 (en) | SYNERGISTIC COMPOSITION OF A CD4-BASED PROTEIN AND ANTIBODY AGAINST HIV-1, AND METHODS OF USE | |
GB2288732B (en) | Pharmaceutical compositions | |
HUP9902068A3 (en) | Methods and compositions for the diagnosis and treatment of cancer | |
IL187254A (en) | ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB | |
IL141686A0 (en) | Methods of treating hypertension and compositions for use therein | |
IL132287A0 (en) | Compositions and methods for the treatment and diagnosis of breast cancer | |
WO2001068697A3 (en) | Methods and compositions for immunoregulation | |
AU9395998A (en) | Compositions and methods for the treatment of immune related diseases | |
HK1071079A1 (en) | Use of soluble fgl2 as an immunosuppressant | |
EP1028754A4 (en) | PREVENTION OF IMMUNE REACTIVITY DUE TO DEPTH OR INHIBITION OF ANTIGENT PRESENTING CELLS | |
HU9600934D0 (en) | Oligopeptides derived from c-reactive protein fragments | |
YU45103A (sh) | Upotreba sarp/1 za lečenje i prevenciju skleroderme | |
ATE316136T1 (de) | Nierenpolycystose-gen | |
EP1023076A4 (en) | USE OF THE P-TEN TUMOR SUPPRESSOR GENE IN THE DIAGNOSIS AND TREATMENT OF CANCER | |
EP1671646A3 (en) | Methods of treating IgE-associated disorders and compositions for use therein | |
EP0891778A3 (en) | Agents for the prevention and/or treatment of radiation-induced disorders | |
ES2122912A1 (es) | Inhibidores de metalocarboxipeptidasas y moleculas derivadas como agentes antitumorales. | |
ZA988293B (en) | Compositions and methods for the treatment of tumor. | |
PL335190A1 (en) | Application of 9,10-seccocholesta-5,7,10(19)-thiene1,3-diole i.e. alphazazidole | |
WO2001062792A3 (en) | Cancer treatment and prognosis involving hes-1 protein | |
MX9710304A (es) | Composiciones para la preparacion de cuero. | |
EP1447089A3 (en) | Methods of treating hypertension and compositions for use therein | |
HU9401579D0 (en) | Methods for administering biological agents and microparticle compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CORR | Corrigendum |
Free format text: CORRECTED DATA OF SECTION 27 TO JOURNAL OF : [73] TRILLIUM THERAPEUTICS INC. - 96 SKYWAY AVENUE, - TORONTO, ONTARIO - M9W 4Y9 - CANADA - DATED 20.10.2006 |
|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20121106 |